Cargando…

Intravenous Liposomal Amphotericin B Efficacy and Safety for Cutaneous and Mucosal Leishmaniasis: A Systematic Review and Meta-analysis

BACKGROUND: Tegumentary leishmaniasis is often subject to limited funding, underpowered studies, and a paucity of high-quality interventional studies. Intravenous liposomal amphotericin B (L-AmB) has been increasingly used to treat cutaneous and mucosal leishmaniasis (CL and ML, respectively) despit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chivinski, Jeffrey, Nathan, Keren, Naeem, Faheel, Ekmekjian, Taline, Libman, Michael D, Barkati, Sapha
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Major Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10372713/ https://www.ncbi.nlm.nih.gov/pubmed/37520422 http://dx.doi.org/10.1093/ofid/ofad348

Ejemplares similares

Intravenous liposomal amphotericin B efficacy and safety for cutaneous and mucosal leishmaniasis: a systematic review and meta-analysis protocol
por: Naeem, Faheel, et al.
Publicado: (2021)

Cutaneous leishmaniasis in a 12-year-old Syrian immigrant
por: Alghounaim, Mohammad, et al.
Publicado: (2022)

Strongyloides stercoralis prevalence in solid-organ and haematopoietic stem cell transplant candidates and recipients: a systematic review and meta-analysis protocol
por: Barkati, Sapha, et al.
Publicado: (2022)

Leishmaniose cutanée observée chez une jeune fille de 12 ans récemment immigrée de Syrie
por: Alghounaim, Mohammad, et al.
Publicado: (2022)

Treatment of Complex Cutaneous Leishmaniasis with Liposomal Amphotericin B
por: Ubals, Maria, et al.
Publicado: (2021)

Liposomal amphotericin B in travelers with cutaneous and muco-cutaneous leishmaniasis: Not a panacea
por: Guery, Romain, et al.
Publicado: (2017)

Cutaneous leishmaniasis in travellers and migrants: a 10-year case series in a Canadian reference centre for tropical diseases
por: Lemieux, Alexandre, et al.
Publicado: (2022)

Development of a topical liposomal formulation of Amphotericin B for the treatment of cutaneous leishmaniasis
por: Jaafari, Mahmoud Reza, et al.
Publicado: (2019)

Liposomal Amphotericin B and Leishmaniasis: Dose and Response
por: Sundar, Shyam, et al.
Publicado: (2010)

962. Cutaneous Leishmaniasis: Investigating Skin Drug Levels to Optimize Liposomal Amphotericin Dosing
por: Aronson, Naomi E, et al.
Publicado: (2018)

Rhinophyma-Like Cutaneous Leishmaniasis due to Leishmania aethiopica Treated Successfully with Liposomal Amphotericin B
por: Kirchberger, Michael Constantin, et al.
Publicado: (2019)

Failure of Liposomal-amphotericin B Treatment for New World Cutaneous Leishmaniasis due to Leishmania braziliensis
por: Kosaka, Atsushi, et al.
Publicado: (2020)

Formulation of Amphotericin B in PEGylated Liposomes for Improved Treatment of Cutaneous Leishmaniasis by Parenteral and Oral Routes
por: Ramos, Guilherme S., et al.
Publicado: (2022)

Liposomal amphotericin B as a treatment for human leishmaniasis
por: Balasegaram, Manica, et al.
Publicado: (2012)

Efficacy of Topical Liposomal Amphotericin B versus Intralesional Meglumine Antimoniate (Glucantime) in the Treatment of Cutaneous Leishmaniasis
por: Layegh, Pouran, et al.
Publicado: (2011)

When Azoles Cannot Be Used: The Clinical Effectiveness of Intermittent Liposomal Amphotericin Prophylaxis in Hematology Patients
por: Batchelor, R, et al.
Publicado: (2021)

Antimony to Cure Visceral Leishmaniasis Unresponsive to Liposomal Amphotericin B
por: Morizot, Gloria, et al.
Publicado: (2016)

Disseminated tegumentary leishmaniasis refractory to liposomal amphotericin B treatment
por: Borges, Ana Flávia, et al.
Publicado: (2021)

Sensitive Molecular Diagnostics for Cutaneous Leishmaniasis
por: Sagi, Orli, et al.
Publicado: (2017)

Comparative efficacy, toxicity and biodistribution of the liposomal amphotericin B formulations Fungisome(®) and AmBisome(®) in murine cutaneous leishmaniasis
por: Wijnant, Gert-Jan, et al.
Publicado: (2018)

Local Skin Inflammation in Cutaneous Leishmaniasis as a Source of Variable Pharmacokinetics and Therapeutic Efficacy of Liposomal Amphotericin B
por: Wijnant, Gert-Jan, et al.
Publicado: (2018)

American cutaneous leishmaniasis in French Guiana: a retrospective comparison between liposomal amphotericin B and meglumine antimoniate
por: Senchyna, A., et al.
Publicado: (2020)

Efficacy of Intralesional Amphotericin B for the Treatment of Cutaneous Leishmaniasis
por: Goyonlo, Vahid Mashayekhi, et al.
Publicado: (2014)

Safety Evaluation of Nano-Liposomal Formulation of Amphotericin B (Sina Ampholeish) in Animal Model as a Candidate for Treatment of Cutaneous Leishmaniasis
por: Eskandari, Seyed Ebrahim, et al.
Publicado: (2018)

Treatment of mucosal leishmaniasis with amphotericin B lipid complex (ABLC)
por: Tuon, Felipe Francisco, et al.
Publicado: (2018)

Estimating direct costs of the treatment for mucosal leishmaniasis in Brazil
por: Carvalho, Janaína de Pina, et al.
Publicado: (2021)

Single High Dose of Liposomal Amphotericin B in Human Immunodeficiency Virus/AIDS-Related Disseminated Histoplasmosis: A Randomized Trial
por: Pasqualotto, Alessandro C, et al.
Publicado: (2023)

Diabetes Modifies the Clinic Presentation of Cutaneous Leishmaniasis
por: Lago, Alexsandro S, et al.
Publicado: (2020)

Comparative study on liposomal amphotericin B and other therapies in the treatment of mucosal leishmaniasis: A 15-year retrospective cohort study
por: Santos, Carolina Rocio, et al.
Publicado: (2019)

Successful treatment of cutaneous protothecosis with liposomal amphotericin and oral itraconazole
por: McMullan, Brendan, et al.
Publicado: (2016)

Pharmacokinetic / pharmacodynamic relationships of liposomal amphotericin B and miltefosine in experimental visceral leishmaniasis
por: Voak, Andrew A., et al.
Publicado: (2021)

Cutaneous parasitism in patients with American visceral leishmaniasis in an endemic area
por: Moura, Carla Riama Lopes de Pádua, et al.
Publicado: (2020)

Prognostic Association of Liposomal Amphotericin B Doses Above 5 mg/kg/d in Mucormycosis: A Nationwide Epidemiologic and Treatment Analysis in Japan
por: Tashiro, Masato, et al.
Publicado: (2023)

Case Report: Use of Liposomal Amphotericin B in Low Doses in Patients With Visceral Leishmaniasis
por: Ren, Danfeng, et al.
Publicado: (2021)

Renal actinomycosis presenting as uro-cutaneous fistula
por: Diab, Christian, et al.
Publicado: (2019)

Activity of Amphotericin B-Loaded Chitosan Nanoparticles against Experimental Cutaneous Leishmaniasis
por: Riezk, Alaa, et al.
Publicado: (2020)

Pharmacodynamics and Biodistribution of Single-Dose Liposomal Amphotericin B at Different Stages of Experimental Visceral Leishmaniasis
por: Voak, Andrew A., et al.
Publicado: (2017)

Parasitological and molecular diagnosis of cutaneous leishmaniasis among indigenous peoples in the state of Roraima, Brazil.
por: de Almeida, Joseneide Viana, et al.
Publicado: (2020)

Liposomal amphotericin B—the present
por: Maertens, J, et al.
Publicado: (2022)

Liposomal amphotericin B—the past
por: Brüggemann, R J, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_9mirl4f9ocv4dk3b9t0n1bqu7n